Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring

A pharmaceutical composition comprising a compound of the formula:

• wherein:
• Y is cyano, heteroaryl(C≦12), substituted heteroaryl(C≦12), or —C(O)Ra, further wherein:
• Ra is:
• hydrogen, hydroxy, halo, amino, azido, mercapto or silyl;
• or
• alkyl(C≦12), alkenyl(C≦12), alkynyl(C≦12), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦12), heteroaralkyl(C≦12), alkoxy(C≦12), alkenyloxy(C≦12), alkynyloxy(C≦12), aryloxy(C≦12), aralkoxy(C≦12), heteroaryloxy(C≦12), heteroaralkoxy(C≦12), acyloxy(C≦12), alkylamino(C≦12), alkoxyamino(C≦12), dialkylamino(C≦12), alkenylamino(C≦12), alkynylamino(C≦12), arylamino(C≦12), aralkylamino(C≦12), heteroarylamino(C≦12), heteroaralkylamino(C≦12), amido(C≦12), or a substituted version of any of these groups;
• and
• X is ORb, or NRbRc, wherein Rb and Rc are each independently:
• hydrogen or hydroxy;
• alkyl(C≦8), aryl(C≦8), aralkyl(C≦8), acyl(C≦8), alkoxy(C≦8), aryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), arylamino(C≦8), amido(C≦8), or a substituted version of any of these groups;
• or
• provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when Rb is absent the atom to which it is bound is part of a double bond;
• or a pharmaceutically acceptable salt, tautomer, or optical isomer thereof;
• and
• a pharmaceutically acceptable carrier.